Catalio Capital Management, LP
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1958125
NEW YORK, NY
Position in PTGX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$13,091,421
New position
Shares Held
106,799
first reported quarter
Ownership
0.165%
of shares outstanding
% of Portfolio
2.46%
of 13F equity value
Holder Rank
#67
of 343 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Catalio Capital Management, LP holds $385,997,200 across 31 Biotechnology names. PTGX ranks #11 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AVLN |
Avalyn Pharma Inc.
|
1,675,830 | $55,168,323 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
455,041 | $33,891,453 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
1,215,698 | $26,575,158 | |
| 4 | DFTX |
Definium Therapeutics, Inc.
|
562,672 | $26,468,090 | |
| 5 | PBLS |
Parabilis Medicines, Inc.
|
824,043 | $22,554,056 | |
| 6 | INCY |
Incyte Corp
|
191,627 | $21,722,836 | |
| 7 | SEPN |
Septerna, Inc.
|
536,152 | $17,955,730 | |
| 8 | MLYS |
Mineralys Therapeutics, Inc.
|
648,722 | $17,502,519 |
All Filings in PTGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,091,421 | 106,799 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||